IMMURON LTD/S ADR (IMRN) stock is higher by 216.14% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With IMRN Stock Today?
IMMURON LTD/S ADR (IMRN) stock is trading at $19.00 as of 9:56 AM on Tuesday, Jul 21, a gain of $8.59, or 82.52% from the previous closing price of $10.41. The stock has traded between $18.25 and $21.30 so far today. Volume today is elevated. So far 8,083,339 shares have traded compared to average volume of 6,077,565 shares.
To see InvestorsObserver's Sentiment Score for IMMURON LTD/S ADR click here.
More About IMMURON LTD/S ADR
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
